Novartis and Medicines for Malaria Venture announce decision

·    Novartis and Medicines for Malaria Venture (MMV) announce decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated

Related Keywords

Singapore , Sweden , Germany , Burkina Faso , Niger , United States , Netherlands , Mali , Kigali , W09 , Rwanda , Gabon , Uganda , Switzerland , France , America , Swiss , Isabella Zinck , African Engl , Arzum Ustun , Nicole Zinsli Somm , Samir Shah , Sujata Vaidyanathan , Parag Mahanti , Julie Masow , Neil Henderson , Africa Burkina Faso , Sloan Simpson , Paul Barasa , Alina Levchuk , Linkedin , Twitter , Novartis Global Health Communications , Genomics Institute Of The Novartis Research Foundation , Novartis External Communications , Novartis , African Media Agency , Singapore Economic Development Board , European Union , Facebook , Wellcome , Head Global Health Development Unit , Drug Administration , World Health Organization , Public Health Institute , Novartis Us External Communications , Saharan Africa Communications , Countries Clinical Trials Partnership , Youtube , Novartis Institute For Tropical Diseases , Malaria Venture , Both Phase , Developing Countries Clinical Trials Partnership , Chief Scientific Officer , Fast Track Designation , Orphan Drug Designation , Eastern Africa , World Malaria Report , Wellcome Trust , Novartis Institute , Tropical Diseases , Genomics Institute , Novartis Research Foundation , Swiss Tropical , Public Health , Kigali Summit , Neglected Tropical Diseases , West African Network , Clinical Trials , Antimalarial Drugs , Health Organization , Media Relations , External Communications , Global Health Communications , Investor Relations , African Media ,